浏览全部资源
扫码关注微信
A New Approach to Network Pharmacological Analysis Based on Key Pathophysiological Processes
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 17, Pages: 203-211(2023)
- 作者机构：
1.南华大学 衡阳医学院 基础医学院，湖南 衡阳 421001
2.郴州市第一人民医院 心血管内科，湖南 郴州 423000
- 作者简介：
- 基金信息：
DOI：10.13422/j.cnki.syfjx.20230814
CLC： R284;R285;R289;R287;R22;R2-031;R33;R24Published：05 September 2023，
Published Online：29 June 2023，
Received：25 April 2023，
- 稿件说明：
扫 描 看 全 文
严易之,李超亚,邓曼菲等.基于关键病理生理学过程的网络药理学分析新思路[J].中国实验方剂学杂志,2023,29(17):203-211.
YAN Yizhi,LI Chaoya,DENG Manfei,et al.A New Approach to Network Pharmacological Analysis Based on Key Pathophysiological Processes[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(17):203-211.
严易之,李超亚,邓曼菲等.基于关键病理生理学过程的网络药理学分析新思路[J].中国实验方剂学杂志,2023,29(17):203-211. DOI： 10.13422/j.cnki.syfjx.20230814.
YAN Yizhi,LI Chaoya,DENG Manfei,et al.A New Approach to Network Pharmacological Analysis Based on Key Pathophysiological Processes[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(17):203-211. DOI： 10.13422/j.cnki.syfjx.20230814.
摘要
近年来网络药理学（NP）领域发展迅猛，但存在缺陷的、套路化的工作流程严重影响了NP分析结果的科学性与可靠性。对于由环境与遗传因素共同导致的复杂疾病，对症治疗或靶向单一病理生理学过程的药物并不能阻止或者延缓病情的进展，因而药物研发失败或退出市场。因此，迫切需要发展结合多个病理生理学过程的NP分析新思路。关键病理生理学过程是疾病的发生发展和转归过程中重要的、成套的病理变化，代表了目前对疾病本质全面的、深刻的认识。为提高NP研究质量、促进NP领域健康发展，该文提出了基于关键病理生理学过程的NP分析的新思路。该方法基于长期中医临床实践与疾病的关键病理生理学过程，从关键病理生理学过程的角度全面解析中药复方药理学机制及活性成分，增加了分析结果的科学性、可靠性与可重复性。本文以阿尔兹海默病（AD）为例阐述了该方法的必要性、可行性、主要工作流程与优缺点等，有望筛选阻止或逆转疾病病程的疾病修饰药物、促进研究成果的临床转化等。
Abstract
In recent years， the field of network pharmacology （NP） has developed rapidly， but the flawed and routine workflow has seriously affected the scientificity and reliability of NP analysis results. For complex diseases caused by environmental and genetic factors， symptomatic treatment or drugs targeting a single pathophysiological process cannot prevent or delay the progression of the disease， so the drug development fails or withdraws from the market. Therefore， there is an urgent need to develop new ideas for NP analysis that combines multiple pathophysiological processes. The key pathophysiological process is an important and complete set of pathological changes in the process of the occurrence， development， and outcome of the disease， which represents the current comprehensive and profound understanding of the nature of the disease. In order to improve the quality of NP research and promote the healthy development of the NP field， this paper proposes a new idea of NP analysis based on key pathophysiological processes. Based on the long-term clinical practice of traditional Chinese medicine and the key pathophysiological process of the disease， the method comprehensively analyzes the pharmacological mechanism and active ingredients of traditional Chinese medicine compound from the perspective of key pathophysiological process， which increases the scientifically， reliability， and repeatability of the analysis results. This paper takes Alzheimer's disease （AD） as an example to illustrate the necessity， feasibility， main workflow， advantages， and disadvantages of this method， and it is expected to screen disease-modifying drugs that prevent or reverse the course of the disease and promote the clinical transformation of research results.
关键词
复杂疾病关键病理生理学过程网络药理学分析新思路阿尔兹海默病
Keywords
complex diseaseskey pathophysiological processesnetwork pharmacology analysisnew ideasAlzheimer’s disease
references
李梢.中医证候与分子网络调节机制的可能关联［C］//中国科学技术协会.中国科协首届学术年会论文集，中国浙江杭州：出版者不详，1999.
HOPKINS A L.Network pharmacology： The next paradigm in drug discovery［J］.Nat Chem Biol，2008，4（11）：682-690.
ZHAO L，ZHANG H，LI N，et al.Network pharmacology，a promising approach to reveal the pharmacology mechanism of Chinese medicine formula［J］.J Ethnopharmacol，2023，309：116306.
SU Y，BAI Q，TAO H，et al.Prospects for the application of traditional Chinese medicine network pharmacology in food science research［J］.J Sci Food Agric，2023
陈健，陈启龙.网络药理学在中医药研究中的现状及思考［J］.上海中医药大学学报，2021，35（5）：1-6，13.
孟凡翠，汤立达.中药网络药理学研究中存在的问题与发展展望［J］.中草药，2020，51（8）：2232-2237.
董培良，李慧，韩华.中药网络药理学的应用与思考［J］.中国实验方剂学杂志，2020，26（17）：204-211.
曾鹏，周航.网络药理学“异病-异方”关键成分筛选同质化现象思考［J］.中国实验方剂学杂志，2022，28（18）：177-191.
世界中医药学会联合会.网络药理学评价方法指南［J］.世界中医药，2021，16（4）：527-532.
JACK C R.Preclinical Alzheimer's disease：A valid concept［J］.Lancet Neurol，2020，19（1）：31.
BRAAK H，BRAAK E.Neuropathological stageing of Alzheimer-related changes［J］.Acta Neuropathol，1991，82（4）：239-259.
FENG L，LI J，ZHANG R.Current research status of blood biomarkers in Alzheimer's disease：Diagnosis and prognosis［J］.Ageing Res Rev，2021，72：101492.
ODDO S，CACCAMO A，SHEPHERD J D，et al.Triple-transgenic model of Alzheimer's disease with plaques and tangles：Intracellular Abeta and synaptic dysfunction［J］.Neuron，2003，39（3）：409-421.
OAKLEY H，COLE S L，LOGAN S，et al.Intraneuronal beta-amyloid aggregates， neurodegeneration， and neuron loss in transgenic mice with five familial Alzheimer's disease mutations： Potential factors in amyloid plaque formation［J］.J Neurosci，2006，26（40）：10129-10140.
PITON M，HIRTZ C，DESMETZ C，et al.Alzheimer's disease：Advances in drug development［J］.J Alzheimers Dis，2018，65（1）：3-13.
MUNJ S M，PATIL P B.Drug Discovery to drug development of BACE1 inhibitor as Antialzheimer's： A review［J］.Curr Top Med Chem，2023，23（2）：77-97.
LACOMME M，HALES S C，BROWN T W，et al.Numb regulates Tau levels and prevents neurodegeneration in tauopathy mouse models［J］.Sci Adv，2022，8（42）：eabm4295.
JACK C R，KNOPMAN D S，JAGUST W J，et al.Tracking pathophysiological processes in Alzheimer's disease：An updated hypothetical model of dynamic biomarkers［J］.Lancet Neurol，2013，12（2）：207-216.
BUSCHE M A，HYMAN B T.Synergy between amyloid-β and tau in Alzheimer's disease［J］.Nat Neurosci，2020，23（10）：1183-1193.
MELNIKOVA I.Therapies for Alzheimer's disease［J］.Nat Rev Drug Discov，2007，6（5）：341-342.
TANZI R E.FDA Approval of Aduhelm paves a new path for Alzheimer's disease［J］.ACS Chem Neurosci，2021，12（15）：2714-2715.
MULLARD A.FDA approval for Biogen's aducanumab sparks Alzheimer disease firestorm［J］.Nat Rev Drug Discov，2021，20（7）：496.
WALSH S，MERRICK R，MILNE R，et al.Aducanumab for Alzheimer's disease？［J］.BMJ， 2021，374：n1682.
RABINOVICI G D.Controversy and progress in Alzheimer's disease -FDA approval of aducanumab［J］.N Engl J Med，2021，385（9）：771-774.
LARKIN H D.Lecanemab gains FDA approval for early Alzheimer disease［J］.JAMA，2023，329（5）：363.
ZHENG R，SHI S，ZHANG Q，et al.Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer's disease by regulating microbiome via network pharmacology and molecular docking analysis［J］.Front Cell Infect Microbiol，2023，13：1140945.
VIJH D，IMAM M A，HAQUE M，et al.Network pharmacology and bioinformatics approach reveals the therapeutic mechanism of action of curcumin in Alzheimer disease［J］.Metab Brain Dis，2023，38（4）：1205-1220.
DING M R，QU Y J，HU B，et al.Signal pathways in the treatment of Alzheimer's disease with traditional Chinese medicine［J］.Biomed Pharmacother，2022，152：113208.
ZENG P，WANG X M，YE C Y，et al.The main alkaloids in uncaria rhynchophylla and their anti-Alzheimer's disease mechanism determined by a network pharmacology approach［J］.Int J Mol Sci，2021，22（7）：3612.
XU M，ZHANG D F，LUO R，et al.A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimer's disease［J］.Alzheimers Dement，2018，14（2）：215-229.
ZENG P，SU H F，YE C Y，et al.Therapeutic mechanism and key alkaloids of uncaria rhynchophylla in Alzheimer's disease from the perspective of pathophysiological processes［J］.Front Pharmacol，2021，12：806984.
ZENG P，SU H F，YE C Y，et al.A tau pathogenesis-based network pharmacology approach for exploring the protections of Chuanxiong Rhizoma in Alzheimer's disease［J］.Front Pharmacol，2022，13：877806.
ZENG P，LIU Y C，WANG X M，et al.Targets and mechanisms of Alpinia oxyphylla Miquel fruits in treating neurodegenerative dementia［J］.Front Aging Neurosci，2022，14：1013891.
曾鹏，叶朝媛，苏泓妃，等.补肾益智方治疗阿尔兹海默病的研究进展［J］.中国实验方剂学杂志，2023，29（1）：270-282.
SU S，CHEN G，GAO M，et al.Kai-Xin-San protects against mitochondrial dysfunction in Alzheimer's disease through SIRT3/NLRP3 pathway［J］.Chin Med，2023，18（1）：26.
XU Y M，LU F M，XU H C，et al.Kai-Xin-San improves cognitive impairment via Wnt/beta-catenin and IRE1/XBP1s signalings in APP/PS1 mice［J］.Rejuvenation Res， 2023，26（3）：105-115.
JIAO Y N，ZHANG J S，QIAO W J，et al.Kai-Xin-San inhibits Tau pathology and neuronal apoptosis in aged SAMP8 mice［J］.Mol Neurobiol，2022，59（5）：3294-3309.
WANG N，JIA Y，ZHANG B，et al.Kai-Xin-San，a Chinese Herbal decoction，accelerates the degradation of β-amyloid by enhancing the expression of neprilysin in rats［J］.Evid Based Complement Alternat Med，2020，2020：3862342.
WANG N，JIA Y M，ZHANG B，et al.Neuroprotective mechanism of Kai Xin San：Upregulation of hippocampal insulin-degrading enzyme protein expression and acceleration of amyloid-beta degradation［J］.Neural Regen Res，2017，12（4）：654-659.
LIN R，YIN J，WU M，et al.Global identification and determination of the major constituents in Kai-Xin-San by ultra-performance liquid chromatography-quadrupole-orbitrap mass spectrometry and gas chromatography-mass spectrometry［J］.J Pharm Biomed Anal，2021，206：114385.
RU J，LI P，WANG J，et al.TCMSP：A database of systems pharmacology for drug discovery from herbal medicines［J］.J Cheminform，2014，6：13.
BANERJEE P，ECKERT A O，SCHREY A K，et al.ProTox-Ⅱ：A webserver for the prediction of toxicity of chemicals［J］.Nucleic Acids Res，2018，46（W1）：W257-W263.
WEI Z，GAO Y，MENG F，et al.iDMer：An integrative and mechanism-driven response system for identifying compound interventions for sudden virus outbreak［J］.Brief Bioinform，2021，22（2）：976-987.
DAINA A，MICHIELIN O，ZOETE V.SwissTargetPrediction：Updated data and new features for efficient prediction of protein targets of small molecules［J］.Nucleic Acids Res，2019，47（W1）：W357-W364.
YU G，WANG L G，YAN G R，et al.DOSE：An R/Bioconductor package for disease ontology semantic and enrichment analysis［J］.Bioinformatics，2015，31（4）：608-609.
梁建文，王晋平，谢荣鑫，等.淫羊藿治疗阿尔茨海默病作用机制的网络药理学与分子对接研究［J］.湖北民族大学学报：医学版，2022，39（1）：6-11.
WANG D，CHEN F，HAN Z，et al.Relationship between amyloid-β deposition and blood-brain barrier dysfunction in Alzheimer's disease［J］.Front Cell Neurosci，2021，15：695479.
STEINMAN J，SUN H S，FENG Z P.Microvascular alterations in Alzheimer's disease［J］.Front Cell Neurosci，2020，14：618986.
KARRAN E，DE STROOPER B.The amyloid hypothesis in Alzheimer disease：New insights from new therapeutics［J］.Nat Rev Drug Discov，2022，21（4）：306-318.
LI S，STERN A M.Bioactive human Alzheimer brain soluble Aβ：Pathophysiology and therapeutic opportunities［J］.Mol Psychiatry，2022，27（8）：3182-3191.
JäKEL L，VAN NOSTRAND W E，NICOLL J，et al.Animal models of cerebral amyloid angiopathy［J］.Clin Sci （Lond），2017，131（19）：2469-2488.
ABUBAKAR M B，SANUSI K O，UGUSMAN A，et al.Alzheimer's Disease：An update and insights into pathophysiology［J］.Front Aging Neurosci，2022，14：742408.
TIKHONOVA M A，AMSTISLAVSKAYA T G，HO Y J，et al.Neuroprotective effects of ceftriaxone involve the reduction of Aβ burden and neuroinflammatory response in a mouse model of Alzheimer's disease［J］.Front Neurosci，2021，15：736786.
程美佳，梁元钰，刘勇明，等.基于网络药理学探讨开心散防治阿尔茨海默病的作用靶点和作用机制［J］.实用中医内科杂志，2021，35（4）：5-9.
0
Views
19
下载量
1
CSCD
- H-PDFDownload
- L-PDFDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Postal code：100700
- Tel：010-84076882 Email：syfjx_2010@188.com
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
